BE900650A - Composition d'endotoxine detoxifiee raffinee et d'un extrait d'un microorganisme soluble dans la pyridine. - Google Patents

Composition d'endotoxine detoxifiee raffinee et d'un extrait d'un microorganisme soluble dans la pyridine.

Info

Publication number
BE900650A
BE900650A BE0/213703A BE213703A BE900650A BE 900650 A BE900650 A BE 900650A BE 0/213703 A BE0/213703 A BE 0/213703A BE 213703 A BE213703 A BE 213703A BE 900650 A BE900650 A BE 900650A
Authority
BE
Belgium
Prior art keywords
composition
extract
detoxified endotoxin
refined detoxified
microorganism
Prior art date
Application number
BE0/213703A
Other languages
English (en)
Inventor
J L Cantrell
Original Assignee
Ribi Immunochem Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribi Immunochem Research Inc filed Critical Ribi Immunochem Research Inc
Publication of BE900650A publication Critical patent/BE900650A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Composition pharmaceutique constituée d'un excipient, d'un extrait soluble dans la pyridine, purifié, d'un microorganisme et d'une endotoxine détoxifiée raffinée. La composition en question convient au traitement de tumeurs cancéreuses. On injecte la composition par la voie parentérale ou directement dans la tumeur.
BE0/213703A 1983-09-23 1984-09-21 Composition d'endotoxine detoxifiee raffinee et d'un extrait d'un microorganisme soluble dans la pyridine. BE900650A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/535,037 US4663306A (en) 1983-09-23 1983-09-23 Pyridine-soluble extract-refined detoxified endotoxin composition and use

Publications (1)

Publication Number Publication Date
BE900650A true BE900650A (fr) 1985-03-21

Family

ID=24132594

Family Applications (1)

Application Number Title Priority Date Filing Date
BE0/213703A BE900650A (fr) 1983-09-23 1984-09-21 Composition d'endotoxine detoxifiee raffinee et d'un extrait d'un microorganisme soluble dans la pyridine.

Country Status (23)

Country Link
US (1) US4663306A (fr)
JP (1) JPS60120817A (fr)
KR (1) KR870000843B1 (fr)
AT (1) AT385659B (fr)
AU (1) AU566234B2 (fr)
BE (1) BE900650A (fr)
CA (1) CA1244765A (fr)
CH (1) CH664897A5 (fr)
DE (1) DE3434766C2 (fr)
DK (1) DK446684A (fr)
ES (1) ES8608872A1 (fr)
FI (1) FI843716L (fr)
FR (1) FR2552326B1 (fr)
GB (1) GB2149301B (fr)
HU (1) HU192585B (fr)
IL (1) IL73034A (fr)
IN (1) IN157240B (fr)
IT (1) IT1179444B (fr)
NL (1) NL8402902A (fr)
NO (1) NO843776L (fr)
NZ (1) NZ209635A (fr)
SE (1) SE8404707L (fr)
ZA (1) ZA847405B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4844894A (en) * 1984-07-12 1989-07-04 Ribi Immunochem Research Inc. Method of inhibiting the onset of septicemia and endotoxemia
US4806352A (en) * 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant
US4877611A (en) * 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4929604A (en) * 1986-05-28 1990-05-29 Board Of Regents, The University Of Texas System Lipopolysaccharides of reduced toxicity and the production thereof
ATE210989T1 (de) * 1993-08-27 2002-01-15 Vetrepharm Inc Zusammensetzung und verfahren zur stimulation der reproduzierenden leistung
BE1007823A3 (fr) * 1993-12-10 1995-10-31 Anda Biolog Sa Utilisation d'une composition comprenant au moins un antigene et/ou un ou plusieurs fragments de cet antigene pour l'obtention d'un medicament destine au traitement et/ou a la prevention du cancer.
US6090385A (en) * 1993-12-10 2000-07-18 Maes; Hubert Method of treating cancer
US5976580A (en) 1995-06-07 1999-11-02 Novus International, Inc. Nutrient formulation and process for enhancing the health, livability, cumulative weight gain or feed efficiency in poultry and other animals
DE19710255A1 (de) * 1997-03-13 1998-09-17 Henkel Ecolab Gmbh & Co Ohg Verwendung einer Lösung zur Desaktivierung von Endotoxinen
AU736450B2 (en) 1997-08-05 2001-07-26 Bioniche Urology Ip Inc. Composition and method for regulating cell proliferation and cell death
US6019985A (en) * 1998-02-27 2000-02-01 Munova Corporation Immunostimulation methods for providing disease protection in poultry
JP4447779B2 (ja) * 1998-07-16 2010-04-07 市郎 東 細菌の菌体成分を有効成分とする癌免疫療法用製剤
CN101491536B (zh) * 1999-12-13 2012-07-04 拜昂尼科生命科学有限公司 治疗用合成寡核苷酸
US7125858B2 (en) * 1999-12-28 2006-10-24 Bioniche Life Sciences Inc. Hyaluronic acid in the treatment of cancer
AU8582701A (en) * 2000-07-11 2002-01-21 Bayer Ag Use of strains of the parapox ovis virus against organ fibrosis
JP4176021B2 (ja) * 2002-03-05 2008-11-05 セルメディシン株式会社 固体化組織免疫アジュバント
AU2003254792A1 (en) * 2002-08-02 2004-02-23 Sumitomo Pharmaceuticals Company, Limited Bacterial cell wall skeleton component preparaion
FR2848223B1 (fr) * 2002-12-09 2005-02-25 Centre Nat Rech Scient Nouveau procede d'isolement des endotoxines.
AU2003261624A1 (en) * 2003-09-05 2005-03-29 Shenyang Sunbellcom Bio-Pharmaceutical Co., Ltd. A red nocardia cell wall skeleton preparation process and its therapeutic use on treating cervical erosion
CA2564180A1 (fr) * 2004-04-22 2005-11-03 Dainippon Sumitomo Pharma Co., Ltd. Preparation pharmaceutique contenant un composant du squelette de la paroi de cellules bacteriennes
AU2014253791B2 (en) 2013-04-18 2019-05-02 Immune Design Corp. GLA monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
CN106661543A (zh) 2014-06-17 2017-05-10 Xycrobe治疗公司 经遗传修饰的细菌和用于细菌的遗传修饰的方法
US11504404B2 (en) 2016-02-24 2022-11-22 Crown Laboratories, Inc. Skin probiotic formulation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7308450A (fr) * 1972-06-20 1973-12-27
FR2269962B1 (fr) * 1974-05-06 1978-02-03 Anvar
JPS58874B2 (ja) * 1979-08-30 1983-01-08 株式会社 目黒研究所 糖蛋白ｗｅｎａｃ及びその製造法
US4436727A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4435386A (en) * 1982-05-26 1984-03-06 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4436728A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
CA1206416A (fr) * 1982-06-30 1986-06-24 John L. Cantrell Extrait de pyridine soluble provenant de microorganismes
CA1206415A (fr) * 1982-06-30 1986-06-24 John L. Cantrell Extrait de pyridine soluble provenant de microorganismes
CA1209504A (fr) * 1982-06-30 1986-08-12 John L. Cantrell Extrait de microorganisme soluble dans la pyridine

Also Published As

Publication number Publication date
SE8404707D0 (sv) 1984-09-20
CH664897A5 (de) 1988-04-15
SE8404707L (sv) 1985-03-24
IN157240B (fr) 1986-02-15
IT1179444B (it) 1987-09-16
ATA302384A (de) 1987-10-15
JPS6254775B2 (fr) 1987-11-17
ZA847405B (en) 1985-05-29
AU3340084A (en) 1985-03-28
ES536167A0 (es) 1986-07-16
DK446684D0 (da) 1984-09-19
HUT35521A (en) 1985-07-29
AU566234B2 (en) 1987-10-15
FI843716L (fi) 1985-03-24
HU192585B (en) 1987-06-29
NO843776L (no) 1985-03-25
DE3434766A1 (de) 1986-04-30
DK446684A (da) 1985-03-24
IL73034A (en) 1988-11-15
DE3434766C2 (de) 1987-05-14
FR2552326A1 (fr) 1985-03-29
NL8402902A (nl) 1985-04-16
KR870000843B1 (ko) 1987-04-25
ES8608872A1 (es) 1986-07-16
AT385659B (de) 1988-05-10
US4663306A (en) 1987-05-05
GB2149301A (en) 1985-06-12
KR850002404A (ko) 1985-05-13
FR2552326B1 (fr) 1988-05-13
JPS60120817A (ja) 1985-06-28
GB8423993D0 (en) 1984-10-31
IT8448894A0 (it) 1984-09-24
NZ209635A (en) 1989-01-27
CA1244765A (fr) 1988-11-15
GB2149301B (en) 1988-06-22
FI843716A0 (fi) 1984-09-21

Similar Documents

Publication Publication Date Title
BE900650A (fr) Composition d'endotoxine detoxifiee raffinee et d'un extrait d'un microorganisme soluble dans la pyridine.
FR2527443B1 (fr) Composition contenant de l'endotoxine raffinee et medicament la contenant
ES8704005A1 (es) Un metodo para evaluar la probabilidad de malignidad celular en una muestra biologica de un haspedante humano.
AU6760987A (en) Method of treating alzheimer's disease
LU91498I2 (fr) Etanercept et ses dérivés pharmaceutiquement acceptables.
NO852872L (no) Fremgangsmaate for fremstilling av nye tetrapyrroler.
ES8207119A1 (es) Procedimiento para preparar complejos de platino (iv)-diami-na.
DE3583008D1 (de) Pharmazeutische zusammensetzungen von dihydrocodeine/ibuprofen und verfahren.
OA07103A (fr) Nouvelles 1,2-diaminocyclobutène-3,4-diones, leur procédé de préparation et composition pharmaceutique les contenant.
OA08694A (fr) Acides 3-pyrrolidinylthio-1-azabicyclo [3.2.0] -hept-2-ène-2-carboxyliques et procédés pour leur préparation.
ES2010561A6 (es) Procedimiento para preparar una composicion farmaceutica a base de un analogo de somatostatina.
ATE232394T1 (de) Verwendung von modifiziertem c-reaktiven protein zur herstellung eines medikaments zur behandlung von krebs
ES2004245A6 (es) Un procedimiento para la produccion de un anticuerpo monoclonal
GB2217330B (en) Lipolytic material associated with cachexia inducing tumours, preparations,production and uses thereof.
HUT61202A (en) Process for producing pharmaceutical compositions neutralizing procoagulant activity caused by tumour cells
DZ1390A1 (fr) Procédé de préparation de dérivés d'acides benzocycloalcényl dihydroxy alcanoïque et de médicaments les contenant.
DE69720783D1 (de) Reaktive sauerstoffverbindungen enthaltende verbindungen zur induzierung von zelldifferentiation maligner zellen so wie leukämie
ES8506806A1 (es) Procedimiento para la preparacion de una proteina hipocolesterolemicamente activa
EP0096007A3 (en) Pharmaceutical preparation containing (+)-cyanidan-3-ol derivatives, the use thereof, novel substituted (+)-cyanidan-3-ol derivatives, and processes for producing them
DE69026371D1 (de) Heilmittel und verfahren zur inhibierung der vaskularisierung von tumoren
EP0295559A3 (en) Pharmaceutical composition for the treatment of tumors
WO1992018536A3 (fr) Procede de detection et de localisation de tissus comprenant des recepteurs de neurokinine 1
FR2631829B1 (fr) Exopolysaccharides fongiques ayant une activite immunostimulante, leur procede d'obtention et composition therapeutique les contenant
IE871358L (en) Interferon for carcinoma
FR2644459B1 (fr) Esters retinoiques de l-cladinose, leur procede de preparation et leur utilisation en medecine humaine ou veterinaire et en cosmetique

Legal Events

Date Code Title Description
RE Patent lapsed

Owner name: RIBI IMMUNOCHEM RESEARCH INC.

Effective date: 19900930